Ohio State Early Investor Network Disclaimer
OSEIN does not provide investment advice, and the information contained in this memo should not be solely relied upon for making investment decisions. Investors are encouraged to conduct their own due diligence and seek professional advice before making any investment. OSEIN does not assume any liability or responsibility for investment outcomes. Additionally, AI was used to review, synthesize, and prepare the following information.
Investing in early-stage and angel investments is inherently risky, and investors should be aware that they may lose their entire investment. By proceeding with any investment, investors acknowledge and assume these risks and understand that the outcomes can be unpredictable and may not result in financial gain.
Company: Biformyx Biofarma
Website: https://biformyxbio.com/
LinkedIn: https://www.linkedin.com/company/biformyx-biopharma-inc/
Venture 360: https://ohiostateearlyinvestornetwork.venture360.co/companies/139361-biformyx-biofarma
Intake Form
BiFormyx BioPharma Presentation - OSEIN.pdf
Financial Overview (1).pptx
Basic Company Information
- Company Name: Biformyx BioFarma
- Business Overview: BiFormyx BioPharma is an innovative biopharmaceutical company developing next-generation dual-payload antibody-drug conjugates (ADCs) to treat aggressive solid tumors, including triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC). Its lead program, BB-001, targets the tumor checkpoint B7-H3 with a dual mechanism: a cytotoxic payload (MMAF) to kill tumor cells, and an immune-stimulating TLR7/8 agonist (IMQ) to activate the tumor microenvironment. BiFormyx holds exclusive licenses from The Ohio State University for its proprietary conjugation platform, which enables flexible payload customization and ratio optimization across multiple oncology indications.
- Overall Raise: The company is currently raising $6–7 million through a post-money SAFE investment. This follows an initial $1 million raise from Camelot BioHoldings LLC . Funds will be deployed toward IND-enabling studies, GMP-scale manufacturing, and early clinical trial preparations, with a goal of achieving Phase 1 clinical proof-of-concept as a key value inflection point.
- The Ohio State Innovation Fund owns 18% equity through the license agreement
- Form of Business Entity: C Corporation
- Patent Status: Two PCT patent applications, exclusively licensed from Ohio State University, cover both the B7-H3 antibody family and dual-payload/linker conjugation technology. These filings provide broad international protection, with formal U.S. and national phase entries planned for 2026.
- Customer Base: BiFormyx’s customers are primarily pharmaceutical partners and investors seeking licensing opportunities or co-development collaborations. Academic partnerships, specifically The Ohio State University, provide clinical development infrastructure.